EarningsQ2 2026 Earnings Report
MX:WST Q2 2026 EPS Results
Actual EPS$42.89
Consensus EPS$37.67
Beat/MissBeat by +$5.21
One Year Ago EPS$33.30
MX:WST Q2 2026 Revenue Results
Actual Revenue$15.79B
Expected Revenue$15.20B
Beat/MissBeat by +$586.67M
YoY Revenue Growth+13.86%
Earnings Announcement Details
QuarterQ2 2026
Date07/23/2026
TimeBefore Open
Conference CallThursday, July 23, 2026
MX:WST Upcoming Earnings
West Pharmaceutical Services's next earnings date is estimated for October 22, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:WST Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was broadly positive: the company reported a clear top‑ and bottom‑line beat, raised full‑year guidance, and demonstrated margin expansion driven by a favorable mix toward high‑value HVP Components, Biologics and Delivery Devices. Management highlighted operational resilience after a cyber incident, strong growth in Asia Pacific, and continued capital returns. Near‑term headwinds include the cyber incident's effect on West Vantage (pushing revenue into later quarters), operating cash‑flow timing pressure, inflationary costs and FX exposure, and the comparability impact from the SmartDose 3.5 divestiture. Overall, the upside from high‑value product mix, margin gains and raised guidance meaningfully outweigh the discrete and manageable lowlights.Company Guidance
Top‑Line Beat and Strong Organic Growth
Q2 revenue of $872 million, up 13.8% reported and ~12.7% organic year‑over‑year; price contributed ~4 percentage points to growth.
Significant EPS Outperformance
Adjusted EPS of $2.37 in Q2, up 29% year‑over‑year and $0.28 above the prior guidance midpoint.
Raised Full‑Year Guidance
Full‑year 2026 organic revenue guidance increased to 10%–11% (from 7%–9%); adjusted EPS guidance raised to $8.85–$9.05 (up ~21%–24% YoY).
HVP Components Drive Durable Growth
HVP Components delivered $424 million in revenue and grew ~18% organic (18.4% cited), now representing 49% of total revenue (vs 46% prior year); both GLP‑1 and non‑GLP‑1 HVP Components expected to grow in the high teens for the year.
Biologics Outperformance
Biologics market group grew ~29% organic in Q2; management reports >90% win rates on new large‑molecule approvals and strong demand for higher‑value FluroTec and NovaPure products.
Delivery Devices and Product Mix Strength
HVP Delivery Devices rose ~29% organic with $131 million in revenue; Standard Products remain a funnel for upgrades while mix shift to higher‑value HVPs is driving margin expansion.
Margin Expansion and Tax Benefit
Total company gross margin 37.7% (+200 basis points YoY) and adjusted operating margin 22.6% (+230 basis points YoY); effective tax rate better than expected at 17.9% in the quarter.
Geographic Breadth and APAC Strength
Delivered double‑digit growth across all three geographies; Asia Pacific led with ~27% organic growth driven by GLP‑1/biosimilar activity in China, India and Korea.
Capital Deployment and Balance Sheet Actions
H1 repurchases of 1.8 million shares for $454 million and $32 million of dividends paid; Q2 repurchase 0.5 million shares for $157 million; capex disciplined ($43 million in Q2; full‑year $250–$275 million guidance unchanged).
Operational Resilience and Strategic Actions
Company executed rapid recovery following a cyber incident, completed SmartDose 3.5 sale on July 1 as planned, and renewed a 50‑year partnership with Daikyo.
MX:WST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed